Frontlight ResearchEarly access
Active, not recruitingNo phase
Sporadic Inclusion Body Myositis Natural History Study
Key facts
- Who runs it
- University of California, Irvine
- Where
- Aurora, Baltimore, Boston, Columbus, Fairway, Houston, Los Angeles, Miami, Orange, Philadelphia, Portland, Seattle, and St Louis, United StatesSee the 13 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 150 people enrolled
- Started
- 11 Oct 2021
- Expected to end
- 31 Mar 2027
- Type of study
- Observational
- Record updated
- 27 May 2026
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Ages 40 years and older
- Fulfills ENMC 2011 criteria of clinically definite or probable sporadic Inclusion body myositis (sIBM)
- Disease onset is within the past 10 years of the time of Baseline visit
- Able to participate and comply with study related procedures
- Able to provide written consent
Who cannot take part
- Current or very recent use (within last 6 months of the Baseline visit) of immunomodulation or immunosuppression therapy
- Current or very recent use (within last 90 days of the Baseline visit) of an investigational medication or therapy
- Co-existing significant medical or surgical conditions that, in the opinion of the investigator, will influence study participation or alter natural history
Where in United States
- University of ColoradoAurora, United States
- Johns Hopkins UniversityBaltimore, United States
- Brigham and Women's HospitalBoston, United States
- Ohio State UniversityColumbus, United States
- Kansas University Medical CenterFairway, United States
- Nerve and Muscle Center of TexasHouston, United States
- University of California, Los AngelesLos Angeles, United States
- University of MiamiMiami, United States
- University of California IrvineOrange, United States
- University of PennsylvaniaPhiladelphia, United States
- Oregon Health Science UniversityPortland, United States
- University of WashingtonSeattle, United States
- Washington University in St. LouisSt Louis, United States
About the trial
What the trial wants to find out
This is a prospective natural history study on patients with clinically defined sIBM. Participants will be assessed every 6 months over two years (five visits total). We will include 150 participants, enrolled across 13 sites, with sporadic IBM, diagnosed according to established criteria.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)
- Record updated
- 27 May 2026